{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:10:42Z","timestamp":1792156242110,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00436-026-08626-0","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:48:32Z","timestamp":1770360512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Formulation and evaluation of amphotericin B emulsion gel against Leishmania major in a murine model: parasite burden, gene expression, and histopathological profiling"],"prefix":"10.1007","volume":"125","author":[{"given":"Nazgol","family":"Safavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Ohadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Dehghannoudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraj","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Salarkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriar","family":"Dabiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"6","key":"8626_CR1","doi-asserted-by":"publisher","first-page":"e0007423","DOI":"10.1371\/journal.pntd.0007423","volume":"13","author":"MR Aflatoonian","year":"2019","unstructured":"Aflatoonian MR et al (2019) Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with Meglumine antimoniate: A cohort study in Iran. PLoS Negl Trop Dis 13(6):e0007423","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"8626_CR2","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s12668-021-00896-5","volume":"11","author":"S Afsharipour","year":"2021","unstructured":"Afsharipour S et al (2021) Preparation and characterization of nano-lipopeptide biosurfactant hydrogel and evaluation of wound-healing properties. BioNanoScience 11(4):1061\u20131069","journal-title":"BioNanoScience"},{"issue":"5","key":"8626_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J et al (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7(5):e35671","journal-title":"PLoS One"},{"issue":"4","key":"8626_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012127","volume":"18","author":"LL Alves","year":"2024","unstructured":"Alves LL, Freire ML, Troian IL, Morais-Teixeira Ed, Cota G (2024) Local amphotericin B therapy for cutaneous leishmaniasis: a systematic review. PLoS Negl Trop Dis 18(4):e0012127","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"8626_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3390\/ph14121253","volume":"14","author":"Z\u0141 Babalska","year":"2021","unstructured":"Babalska Z\u0141, Korbecka-Paczkowska M, Karpi\u0144ski TM (2021) Wound antiseptics and European guidelines for antiseptic application in wound treatment. Pharmaceuticals 14(12):1253","journal-title":"Pharmaceuticals"},{"key":"8626_CR6","doi-asserted-by":"publisher","unstructured":"Bagheri AM, Ranjbar M (2025) A Novel Platform for Controlled Drug Delivery and Dye Removal; Green Synthesis and Characterization of Honey-Incorporated Cu\/Al Layered Double Hydroxide (LDH) Nanocomposite. Jundishapur J Nat Pharm Prod 20(1):e154579. https:\/\/doi.org\/10.5812\/jjnpp-154579","DOI":"10.5812\/jjnpp-154579"},{"issue":"7","key":"8626_CR7","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s10876-024-02651-8","volume":"35","author":"AM Bagheri","year":"2024","unstructured":"Bagheri AM et al (2024) Curcumin nanoemulgel: characterization, optimization, and evaluation of photoprotective efficacy, anti-inflammatory properties, and antibacterial activity. J Cluster Sci 35(7):2253\u20132272","journal-title":"J Cluster Sci"},{"issue":"16","key":"8626_CR8","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.2174\/0929867327666200831125656","volume":"28","author":"FG Baveloni","year":"2021","unstructured":"Baveloni FG, Riccio BV, Di Filippo LD, Fernandes MA, Meneguin AB, Chorilli M (2021) Nanotechnology-based drug delivery systems as potential for skin application: a review. Curr Med Chem 28(16):3216\u20133248","journal-title":"Curr Med Chem"},{"issue":"5","key":"8626_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001622","volume":"6","author":"MM Costa","year":"2012","unstructured":"Costa MM et al (2012) Improved canine and human visceral leishmaniasis immunodiagnosis using combinations of synthetic peptides in enzyme-linked immunosorbent assay. PLoS Negl Trop Dis 6(5):e1622","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"8626_CR10","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.1021\/acs.molpharmaceut.4c00485","volume":"21","author":"SK Dash","year":"2024","unstructured":"Dash SK, Benival D, Jindal AB (2024) Formulation strategies to overcome amphotericin B induced toxicity. Mol Pharm 21(11):5392\u20135412","journal-title":"Mol Pharm"},{"issue":"6","key":"8626_CR11","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s13346-020-00821-5","volume":"10","author":"AP dos Santos Matos","year":"2020","unstructured":"dos Santos Matos AP et al (2020) Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions. Drug Delivery Translational Res 10(6):1552\u20131570","journal-title":"Drug Delivery Translational Res"},{"key":"8626_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.124538","volume":"241","author":"MAR Estabragh","year":"2023","unstructured":"Estabragh MAR, Bami MS, Dehghannoudeh G, Noudeh YD, Moghimipour E (2023) Cellulose derivatives and natural gums as gelling agents for preparation of emulgel-based dosage forms: a brief review. Int J Biol Macromol 241:124538","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"8626_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012175","volume":"18","author":"BA Ferreira","year":"2024","unstructured":"Ferreira BA et al (2024) Amphotericin B resistance in Leishmania amazonensis: in vitro and in vivo characterization of a Brazilian clinical isolate. PLoS Negl Trop Dis 18(5):e0012175","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"8626_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/pharmaceutics15010099","volume":"15","author":"F Fr\u00e9zard","year":"2022","unstructured":"Fr\u00e9zard F et al (2022) Liposomal amphotericin B for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations. Pharmaceutics 15(1):99","journal-title":"Pharmaceutics"},{"issue":"8","key":"8626_CR15","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.3109\/10717544.2016.1153747","volume":"23","author":"A Hussain","year":"2016","unstructured":"Hussain A, Singh VK, Singh OP, Shafaat K, Kumar S, Ahmad FJ (2016) Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of amphotericin B. Drug Deliv 23(8):3101\u20133110","journal-title":"Drug Deliv"},{"issue":"10","key":"8626_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2217\/nnm-2020-0482","volume":"16","author":"M Jafari","year":"2021","unstructured":"Jafari M, Abolmaali SS, Tamaddon AM, Zomorodian K, Shahriarirad B (2021) Nanotechnology approaches for delivery and targeting of amphotericin B in fungal and parasitic diseases. Nanomedicine 16(10):857\u2013877","journal-title":"Nanomedicine"},{"key":"8626_CR17","doi-asserted-by":"crossref","unstructured":"Kumar M, Pathak D (2025) A Comprehensive Review of Nanotechnology Based Nanoemulsion Delivery Systems for Targeted Drug Delivery and Enhanced Therapeutic Efficacy. Pharmaceutical Nanotechnology","DOI":"10.2174\/0122117385388338250711001010"},{"issue":"10","key":"8626_CR18","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1128\/AAC.02343-12","volume":"57","author":"AH Mohamed-Ahmed","year":"2013","unstructured":"Mohamed-Ahmed AH, Seifert K, Yardley V, Burrell-Saward H, Brocchini S, Croft SL (2013) Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly (\u03b1-glutamic acid) complex. Antimicrob Agents Chemother 57(10):4608\u20134614","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"8626_CR19","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1021\/acsinfecdis.1c00245","volume":"7","author":"C Morelle","year":"2021","unstructured":"Morelle C et al (2021) Well-tolerated amphotericin B derivatives that effectively treat visceral leishmaniasis. ACS Infect Dis 7(8):2472\u20132482","journal-title":"ACS Infect Dis"},{"key":"8626_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117109","volume":"178","author":"MK Nahanji","year":"2024","unstructured":"Nahanji MK et al (2024) Enhancing the efficacy of fluconazole against leishmania major: formulation and evaluation of FLZ-nanoemulsions for topical delivery. Biomed Pharmacother 178:117109","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"8626_CR21","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.2174\/0115701808346130241213093236","volume":"21","author":"A Pardakhty","year":"2024","unstructured":"Pardakhty A, Rajaei P, Ranjbar M, Ohadi M (2024) Preparation and evaluation of Ni\/NiAl2O4 core\/shell nanostructures in non-ionic surfactant-based vesicle. Lett Drug Des Discov 21(18):4500\u20134507","journal-title":"Lett Drug Des Discov"},{"key":"8626_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.colsurfb.2015.12.003","volume":"139","author":"AP Perez","year":"2016","unstructured":"Perez AP et al (2016) Topical amphotericin B in ultradeformable liposomes: formulation, skin penetration study, antifungal and antileishmanial activity in vitro. Colloids Surf B Biointerfaces 139:190\u2013198","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"3","key":"8626_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/20477724.2018.1447836","volume":"112","author":"M Ramezany","year":"2018","unstructured":"Ramezany M et al (2018) Geographical distribution and molecular characterization for cutaneous leishmaniasis species by sequencing and phylogenetic analyses of kDNA and ITS1 loci markers in south-eastern Iran. Pathog Glob Health 112(3):132\u2013141","journal-title":"Pathog Glob Health"},{"issue":"6","key":"8626_CR24","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1039\/C6TX00253F","volume":"5","author":"DC Santos","year":"2016","unstructured":"Santos DC et al (2016) Metabolomics as a tool to evaluate the toxicity of formulations containing amphotericin B, an antileishmanial drug. Toxicol Res 5(6):1720\u20131732","journal-title":"Toxicol Res"},{"issue":"6","key":"8626_CR25","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001333","volume":"70","author":"F Sharifi","year":"2021","unstructured":"Sharifi F et al (2021) Leishmanicidal potentials of Gossypium hirsutum extract and its fractions on Leishmania major in a murine model: parasite burden, gene expression, and histopathological profile. J Med Microbiol 70(6):001333","journal-title":"J Med Microbiol"},{"key":"8626_CR26","doi-asserted-by":"publisher","first-page":"1091709","DOI":"10.3389\/fpubh.2023.1091709","volume":"11","author":"I Sharifi","year":"2023","unstructured":"Sharifi I et al (2023) Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in Preparation for an elimination plan. Front Public Health 11:1091709","journal-title":"Front Public Health"},{"key":"8626_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2024.108859","volume":"267","author":"I Sharifi","year":"2024","unstructured":"Sharifi I, Salarkia E, Dabiri S, Pardakhty A, Sharifi F, Mohamadi N (2024) Preparation, characterization, and in vivo activity of Gossypium hirsutum niosomes against cutaneous leishmaniasis caused by Leishmania major in a murine model: parasite burden, gene expression, and histopathological profiling. Exp Parasitol 267:108859","journal-title":"Exp Parasitol"},{"issue":"11","key":"8626_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112316","volume":"14","author":"E Wasan","year":"2022","unstructured":"Wasan E, Mandava T, Crespo-Moran P, Nagy A, Wasan KM (2022) Review of novel oral amphotericin B formulations for the treatment of parasitic infections. Pharmaceutics 14(11):2316","journal-title":"Pharmaceutics"},{"key":"8626_CR31","doi-asserted-by":"crossref","unstructured":"Wasan KM (2024) Development and deployment of a solid oral amphotericin B dosage form to treat visceral leishmaniasis within apediatric population. PLOS Neglected Tropical Diseases 18(9):e0012500","DOI":"10.1371\/journal.pntd.0012500"},{"key":"8626_CR29","unstructured":"World Health Organization (WHO) (2022) Leishmaniasis\u2014Key facts. Geneva Swiss. https:\/\/www.who.int\/news-room\/factsheets\/detail\/leishmaniasis"},{"issue":"1","key":"8626_CR30","doi-asserted-by":"publisher","first-page":"e0012735","DOI":"10.1371\/journal.pntd.0012735","volume":"19","author":"H Zhang","year":"2025","unstructured":"Zhang H et al (2025) Progress in antileishmanial drugs: Mechanisms, challenges, and prospects. PLoS Negl Trop Dis 19(1):e0012735","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00436-026-08626-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-026-08626-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-026-08626-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:29:51Z","timestamp":1770362991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00436-026-08626-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["8626"],"URL":"https:\/\/doi.org\/10.1007\/s00436-026-08626-0","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"value":"0932-0113","type":"print"},{"value":"1432-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical committee of Kerman University of Medical Sciences approved it. The Ethic approval Code is IR.KMU.REC.1399.173.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"17"}}